Core Viewpoint - Jiuzhou Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Tofisopam Tosylate, an oral anticoagulant drug aimed at preventing strokes and systemic embolism in patients with non-valvular atrial fibrillation, as well as treating or preventing deep vein thrombosis and pulmonary embolism [1] Company Summary - The company submitted the marketing application for Tofisopam Tosylate to the National Medical Products Administration in July 2024 and has recently obtained the approval notification [1] - Cumulative research and development investment in Tofisopam Tosylate has reached approximately RMB 6.69 million [1] Industry Summary - The main manufacturers of Tofisopam Tosylate in China include Xiansheng Pharmaceutical Co., Ltd. and Shandong New Era Pharmaceutical Co., Ltd. [1] - Sales of Tofisopam Tosylate tablets in domestic sample hospitals and urban pharmacies amounted to approximately RMB 361 million in 2023 [1]

Core Viewpoint - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. has received a drug registration certificate for Tanshinone IIA from the National Medical Products Administration, which enhances its product pipeline and market competitiveness [1][3]. Drug Basic Information - The drug name is Tanshinone IIA, available in tablet form with specifications of 60mg and 30mg [1]. - It is classified as a Class 4 chemical drug with registration numbers H20255929 and H20255930, valid until November 11, 2030 [1]. - The drug is produced by Jiuzhou Biopharmaceutical (Taizhou) Co., Ltd., located in Taizhou, Zhejiang Province [1]. Market Context - Tanshinone IIA is an oral anticoagulant primarily used for preventing strokes and systemic embolism in patients with non-valvular atrial fibrillation, as well as treating or preventing deep vein thrombosis and pulmonary embolism [2]. - The drug was first developed by Daiichi Sankyo in Japan and launched in April 2011 [2]. - In 2023, the sales revenue of Tanshinone IIA in domestic sample hospitals and pharmacies was approximately RMB 361 million [2]. - The company has invested about RMB 14.41 million in the research and development of Tanshinone IIA [2]. Impact on the Company - The acquisition of the drug registration certificate for Tanshinone IIA will enrich the company's product pipeline and enhance its market competitiveness [3]. - However, this development is not expected to have a significant short-term impact on the company's performance [3].

Group 1: Company Announcements - 合富中国's stock price increased by 256.29% over 14 trading days, significantly outperforming the industry and Shanghai Composite Index, leading to a suspension for verification starting November 17 [1] - 工业富联's GB300 achieved mass production in Q3, with improved yield and testing efficiency, positively impacting Q4 gross margin [2] - 天孚通信's controlling shareholder plans to transfer 8.5 million shares, representing 1.09% of total equity, due to personal funding needs [4] - 璞泰来 plans to invest 7.6 billion yuan in a new integrated film coating project, aiming to meet growing demand in the battery and energy storage sectors [5] - 电投能源 intends to acquire 100% of Baiyin Hua Coal Power for 11.149 billion yuan, financing through share issuance and cash [6] - 中微公司 reported that a shareholder completed a reduction of 12.52 million shares, totaling 3.351 billion yuan [7] - 瑞德智能 plans to invest 10 million yuan in a leading company in the power plant robotics sector [8] - 盘古智能 aims to acquire control of a petrochemical company by purchasing 11.97% of its shares for 24.64 million yuan [9] - 泰达股份 signed a memorandum for a waste-to-energy project in Egypt [10] - 杭氧股份 is set to establish a venture capital fund focusing on low-temperature technology and nuclear fusion [11] Group 2: Financial Performance and Regulatory Approvals - 复星医药's subsidiary received FDA approval for a biosimilar drug, with applications pending in China and Europe [21] - 长春高新 received approval for a clinical trial of a new growth hormone drug, with no similar products currently available in China [20] - 海辰药业 obtained a drug registration certificate for a new injection product [22] - 上海机场 reported a 12.46% year-on-year increase in passenger throughput for October [23] Group 3: Shareholder Actions - 深桑达 A plans to publicly transfer 80% of a subsidiary's shares with a minimum price of 1.857 billion yuan [12] - 中电港's major shareholder reduced its stake by 1% between October 31 and November 13 [15] - 康龙化成's major shareholders plan to collectively reduce their holdings by up to 1.5% [16] - 科兴制药's controlling shareholder intends to transfer 5% of its shares [17]

Core Viewpoint - Jiuzhou Pharmaceutical announced the approval of its subsidiary Jiuzhou Biopharmaceutical (Taizhou) Co., Ltd. for the registration of Tofacitinib Tablets by the National Medical Products Administration [1] Company Summary - Jiuzhou Pharmaceutical's subsidiary received the drug registration certificate for Tofacitinib Tablets, previously known as Zhejiang Siwei Pharmaceutical Technology Co., Ltd. [1]

Core Viewpoint - The company has received approval for the registration certificate of Tofacitinib Tosylate Tablets, enhancing its product pipeline and market competitiveness [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Jiuzhou Biopharmaceutical (Taizhou) Co., Ltd., has obtained the drug registration certificate from the National Medical Products Administration for Tofacitinib Tosylate Tablets [1] - Tofacitinib Tosylate is an oral anticoagulant primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1] Group 2: Market Impact - The acquisition of the drug registration certificate will further enrich the company's product pipeline and help enhance its market competitiveness [1] - The recent approval is not expected to have a significant short-term impact on the company's performance [1] Group 3: Industry Characteristics - The production and sales of pharmaceutical products are influenced by market conditions, industry policies, and supply-demand relationships, which introduces a degree of uncertainty [1]

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) announced that its wholly-owned subsidiary, Jiuzhou Biopharmaceutical (Taizhou) Co., Ltd., has received the drug registration certificate for Edoxaban Tosilate Tablets from the National Medical Products Administration [1] Group 1: Company Developments - Jiuzhou Biopharmaceutical has been granted approval for Edoxaban Tosilate, an oral anticoagulant [1] - The drug is primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1] - Edoxaban Tosilate was originally developed by Daiichi Sankyo in Japan and was launched in Japan in April 2011 [1] Group 2: Industry Context - Other manufacturers in China that have obtained registration for Edoxaban include Hainan Sinopharm and Shandong New Era Pharmaceutical [1]

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) has received approval from the National Medical Products Administration for the registration of Tofisopam Tosylate Tablets, marking a significant milestone for the company in the oral anticoagulant market [1] Group 1: Company Developments - Jiuzhou Pharmaceutical's wholly-owned subsidiary, Jiuzhou Biopharmaceutical (Taizhou) Co., Ltd., has been granted the Drug Registration Certificate for Tofisopam Tosylate Tablets [1] - The drug is primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1] Group 2: Industry Context - Tofisopam Tosylate was originally developed by Daiichi Sankyo in Japan and was launched in April 2011 [1] - Other manufacturers in China that have obtained registration for this drug include Hainan Xiansheng Pharmaceutical Co., Ltd. and Shandong New Era Pharmaceutical Co., Ltd. [1]

Investment Rating - The investment rating for the company is "Add" [1] Core Views - The company has shown continuous improvement in operational efficiency and has good growth potential in its CSO (Contract Sales Organization) business [4] - Key products have maintained stable growth, with significant sales increases in certain categories due to marketing reforms and favorable policy changes [6] - The company has a strong foundation in its CSO business, with ongoing collaborations expected to contribute to revenue growth [6] - Earnings forecasts indicate a slight decline in revenue for 2025, followed by a recovery and growth in subsequent years, with net profit expected to grow steadily [5][6] Financial Summary - The latest closing price is 3.39 CNY, with a one-year high of 4.08 CNY and a low of 1.80 CNY [3] - The current P/E ratio is 31.43, and the P/B ratio is 3.72 [3] - Total shares outstanding are 2.246 billion, with a total market capitalization of 7.613 billion CNY [3] - Revenue for 2024 is projected at 24.41 billion CNY, with a slight decline in 2025 to 24.37 billion CNY, followed by growth to 27.51 billion CNY in 2026 and 30.80 billion CNY in 2027 [5] - Net profit for 2024 is estimated at 2.33 billion CNY, increasing to 2.56 billion CNY in 2025, 2.91 billion CNY in 2026, and 3.28 billion CNY in 2027 [5] - The company’s sales expense ratio has decreased by 8.30 percentage points year-on-year, and management expenses have decreased by 21.58% [6]